Journal of Current Hematology & Oncology Research最新文献

{"title":"Relationship between pancreatic cancer and Maresin 1","authors":"Hakan Varol, Özlem Gül, B. Ergül, Üçler Kısa, E. Tekin, D. Oğuz","doi":"10.51271/jchor-0006","DOIUrl":"https://doi.org/10.51271/jchor-0006","url":null,"abstract":"Aims: Pancreatic cancer is the 4th most common cause of death from cancer. In addition, pancreatic cancer is the most \u0000common primary malignant tumor of the pancreas. There are many risk factors for pancreatic cancer, including age, certain \u0000genetic syndromes, smoking, diabetes, alcohol abuse and obesity. In our study, we aimed to evaluate the role of Maresin 1 \u0000(MaR1), which is responsible for the resolution of inflammation, in the pathogenesis of pancreatic cancer and its differential \u0000power between chronic pancreatitis and pancreatic cancer.\u0000Methods: The study included 47 patients diagnosed with pancreatic cancer, 32 patients diagnosed with chronic pancreatitis, \u0000and 30 volunteers without any additional disease who applied to the internal medicine polyclinic for routine control, who \u0000applied to our clinic since October 2021 and accepted to participate in the study. MaR1 levels were measured using the ELISA technique from blood samples obtained from these volunteers.\u0000Results: In our study, MaR1 level was 374.42 (97.27-74.129) pg/ml in the pancreatic cancer group, 491.39 (252.66-949.28) pg/ml in the chronic pancreatitis group and 558.53 (286.94) in the healthy control group. -886,68) pg/ml was measured. There was a significant difference between the pancreatic cancer patients group and the chronic pancreatitis patients and healthy control group. In the pancreatic cancer patient group, MaR1 level was found to be lower than the chronic pancreatitis group (p=0.01). In our ROC analysis, the discriminative performance of MaR1 (AUC=0.651; [95%CI: 0.535-0.754]; p=0.0169 values) was found to be high in predicting patients with pancreatic cancer according to the patient group with chronic pancreatitis. For MaR1 ?315.52 cut-off point sensitivity was 36.17% and selectivity was 90.62%.\u0000Conclusion: Proinflammatory cytokines, which have a role in the pathogenesis of pancreatic cancer, increase as a result \u0000of the decrease in lipid mediators involved in resolution pathways. Reduction of MaR1 may trigger chronic inflammation \u0000and pancreatic carcinogenesis. MaR1 may make an important diagnostic contribution in clinical practice in predicting the \u0000progression of patients with chronic pancreatitis to pancreatic cancer.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122947254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer patient characteristics in a city in the Central Anatolian Region of Turkey: A single-center descriptive study","authors":"Mustafa Büyükkör, Fatih Tay, Ayşegül Özakyol Harmancı","doi":"10.51271/jchor-0009","DOIUrl":"https://doi.org/10.51271/jchor-0009","url":null,"abstract":"Aims: This study aimed to determine the characteristics of patients with gastric cancer living in Eskişehir, a city located \u0000in the central Anatolian region of Turkey, together with factors affecting the recurrence and survival time.\u0000Methods: This descriptive cross-sectional study was conducted using patients records who were admitted to Eskişehir \u0000Osmangazi University Health Practice and Research Hospital, Department of Internal Medicine between December 1998 \u0000and January 2011 with a diagnosis of gastric cancer. Missing data was obtained by calling the patients or their relatives by \u0000phone.\u0000Results: We evaluated 210 gastric cancer patients in this study.Male sex was approximately 2.5 times dominant, and most \u0000of the patients were diagnosed between the ages of 60-69. Approximately 1/5th of the patients applied to the health center \u00006 months after the onset of symptoms. Age, chemotherapy, and radiotherapy were significantly related to recurrence \u0000(p=0.028, p=0.009, and p=0.005, respectively). Stage, area of involvement, positive surgical margin, chemotherapy, \u0000radiotherapy, and the number of lymph nodes removed were significantly related to survival time (p<0.001 for all \u0000variables).\u0000Conclusion: In the studied population, gastric cancer diagnosis is delayed in a significant proportion of symptomatic \u0000patients. To decrease missed diagnoses, health professionals, especially those working in primary health care, should \u0000be made more sensitive towards the red flags of gastric cancer. Chemotherapy and radiotherapy are effective treatment \u0000options in preventing recurrences and improving survival.\u0000","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132321611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of relationship between hyperuricemia and hyperhomocysteinemia","authors":"Kemalettin Yılmaz, İ. Ç. Özdemir","doi":"10.51271/jchor-0008","DOIUrl":"https://doi.org/10.51271/jchor-0008","url":null,"abstract":"Aims: Hyperuricemia is generally a subclinical disorder. Uric acid takes part in the malignities, obesity-insulin resistance \u0000syndrome, and some other cardiovasculer problems. Plasma homocysteine (Hcy) levels are one of the major risk factors of \u0000coronary heart disease, one of the major reasons of adult mortality. In this study, it was aimed to determine relationship \u0000between hyperuricemia and hyperhomocysteinemia. \u0000Methods: In this prospective research, 32 patients and 32 healthy controls were investigated. The age, sex, height, weight, \u0000complaints, medications and arterial blood pressure of the patients were measured and recorded. Moreover, whole blood test, fasting plasma glucose, serum lipids, sedimentation, cobalamin, folate, plasma total Hcy and uric acid levels were determined.\u0000Results: In the patient group 62.51% was male and 37.5% was female. The mean age was 54.69+12.03. In the healthy controls 62.5% was male and 37.5% was female, and the mean age was 51.59+9.57. The difference between the mean ages of both groups was not significant (p>0.05). Uric acid levels were found to be 8.61±0.98 mg/dl in the patient group and 4.09±0.99 mg/dl in the control group, and this difference was significant (p<0.001). Hcy levels were found to be 10.99+1.42 µmol/L in the patient group and 6.67±0.80 gmoI/L in the control group. This difference was also statistically significant (p<0.001)\u0000Conclusion: Hyperuricemia which is generally a subclinical disorder is accepted a coronary risk factor with the presence of \u0000other risks. Elevated plasma homocysteine is an independent risk factor for coronary heart disease. There are similar features of the both etiologia. Therefore we recommend to calculate the plasma homocysteine levels in hyperuricemic patients who have the risk of coronary heart disease and to treat the hyperuricemic patients having hyperhomocysteinemia and coronary risk factors.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130855971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of initial sodium and globulin values in the prognosis prediction of patients diagnosed with colon cancer","authors":"Yusufcan Yavaş, S. Yalçın, Hatice Keleş","doi":"10.51271/jchor-0007","DOIUrl":"https://doi.org/10.51271/jchor-0007","url":null,"abstract":"Aims: Early prediction of prognosis in malignancies can help determine life expectancy and take necessary further measures \u0000accordingly. There is no consensus on using any biomarker in predicting prognosis in colon cancer cases. A study reported that the sodium/globulin ratio is a valuable biomarker in predicting the prognosis of gastric cancer. This study aimed to investigate the role of baseline sodium, globulin, and sodium/globulin ratio in the prediction of prognosis and survival in colon cancer cases.\u0000Methods: The files of patients diagnosed with colon cancer who applied to Kırıkkale University Faculty of Medicine Medical \u0000Oncology Clinic between January 1, 2015, and December 31, 2020, were retrospectively analyzed. The relationship between the clinical and laboratory characteristics of the cases and their progression and survival were investigated.\u0000Results: 140 patients diagnosed with colon cancer were included in the study (82 men, 58 women). The average age at diagnosis was 64.1±12.6 years, 99.3% of them were adenocarcinoma, and 32.9% of them were stage 4 cancers. It was determined that 42.1% of the patients died (average survival time 54.0±3.2 months), and progression developed in 18.6% during the study period. The average baseline sodium/globulin ratio was 51.10±8.70. No significant correlation was found between initial serum sodium level, globulin level, sodium/globulin ratio, survival time, and progression status (p>0.05). Baseline serum globulin level showed a weak negative correlation with both progression-free and overall survival time (r=-0.23, p<0.05 and r=-0.24, p<0.05, respectively), while the sodium/globulin ratio showed a weak positive correlation with progression-free survival time (r=0.26, p<0.01) and overall survival time (r=0.25, p<0.01). The ROC curve analysis determined that initial serum sodium and globulin levels and sodium/globulin ratio were not predictive of progression and survival at any cut-off point (p>0.05).\u0000Conclusion: Although baseline serum sodium level, globulin level, and serum sodium/globulin ratio were weakly correlated \u0000with progression-free and overall survival time of patients diagnosed with colon cancer, they were not valuable in predicting \u0000progression and survival.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122295183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID 19 antibody level in hematological patients","authors":"Ahmet Kaya, İ. Berber, I. Kuku, M. Erkurt, E. Kaya, S. Biçim, Emine Hidayet, Salih Cırık, Süleyman Arslan, F. Yağın, A. Sarici","doi":"10.51271/jchor-0001","DOIUrl":"https://doi.org/10.51271/jchor-0001","url":null,"abstract":"Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors.\u0000Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA).\u0000Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group.\u0000Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"191 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133898471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of presepsin level and bacterial infection in neutropenic patients","authors":"Merve Genç, S. Yalçın, Üçler Kısa","doi":"10.51271/jchor-0002","DOIUrl":"https://doi.org/10.51271/jchor-0002","url":null,"abstract":"Aim: Neutropenia is a life-threatening condition that is seen as a complication of chemotherapy, especially in cancer patients, if the patient is infected. Early treatment of the infection has aimportant effect on mortality. Our aim in this study is to investigate the usability of presepsin in terms of diagnosis of bacterial infection in patients who are neutropenic after chemotherapy.\u0000Methods: In this study, presepsin, erythrocyte sedimentation rate (ESR), CRP (C-reactive protein), and procalcitonin were measured in 25 neutropenic patients, and a comparison was made between those who were culture positive and negative, those who had a fever and those who did not. In addition, presepsin and CRP values were compared with the control group of 22 people.\u0000Results: Presepsin, CRP, ESR and procalcitonin were significantly higher in those who did not reproduce in each culture (p<0.001, p=0.003, p=0.026, p<0.01, respectively) compared to those who did not have a fever (p<0.001, p<0.001, p < 0.001, p=0.019, respectively). \u0000Conclusion: Presepsin has the potential to be used in the early evaluation of bacterial infection in neutropenic patients. However, more work should be done on this issue.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131078286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of dapsone-induced hemolytic anemia related to G6PD enzyme deficiency","authors":"Ali Doğan, Narin Yıldırım Doğan, Ömer Ekinci, Sinan Demircioğlu, C. Demir, Cihan Ural, R. Esen","doi":"10.51271/jchor-0005","DOIUrl":"https://doi.org/10.51271/jchor-0005","url":null,"abstract":"Hemolytic anemia is characterized by a decrease in the number of circulating erythrocytes due to an increase in their hemolysis. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common erythrocyte enzyme defects related to hemolysis. The G6PD enzyme abrogates the hemolysis of erythrocytes by protecting them against oxidative stress due to its involvement in the glutathione metabolism. G6PD enzyme deficiency-related hemolytic anemia may present as neonatal jaundice or become manifest due to exposure to infections, favism and medications later in life. Dapsone is a medication that is preferred by doctors in the treatment of many dermatological disorders such as pemphigus vulgaris, and leads to hemolysis in the presence of G6PD enzyme deficiency. In this type of non-immune hemolysis, haptoglobulin is low and Coombs' tests are negative. Hemolytic anemia, a serious complication that may appear subsequent to dapsone use, can be prevented by testing G6PD enzyme levels prior to dapsone therapy. In this case, we emphasized that the hemolytic anemia in the patient using dapsone may be due to G6PD enzyme deficiency.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115401365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor markers: when, whom?","authors":"Artuner Varlıbaş, A. Çi̇fci̇","doi":"10.51271/jchor-0003","DOIUrl":"https://doi.org/10.51271/jchor-0003","url":null,"abstract":"Cancer is a leading health problem with its prevalence, clinical course and deaths all over the world. It is known that cancer is the second leading cause of death in Turkey after cardiovascular diseases. Therefore, intensive research is carried out on the early diagnosis and treatment of cancer. The most important of these are tumor markers that are still used in clinical practice. Based on this definition, it is theoretically possible to obtain information about the presence of the tumor and the character of the tumor by investigating tumor markers in body fluids. A tumor marker is a molecule that is present in the structure of the tumor cell, secreted by the tumor cell or produced in response to the tumor and can be measured or demonstrated in body fluids. However, its use is limited due to its low sensitivity and specificity to cancer type in the early period. Therefore, it is important to select the appropriate test at the appropriate time for the appropriate patient. In this review, general principles regarding the use of tumor markers were tried to be explained.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"155 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127611409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of malignant melanoma presented with lombar vertebra fracture","authors":"A. Sarici, I. Kuku, İ. Berber, M. Erkurt, H. Ulubaba, S. Biçim, M. Durmuş, E. Kaya","doi":"10.51271/jchor-0004","DOIUrl":"https://doi.org/10.51271/jchor-0004","url":null,"abstract":"Aims: Malignant melanoma is a type of skin cancer with a very poor prognosis. It is the most common skin cancer. Metastases are frequently observed in malignant melanoma, which can have a very aggressive course, even without skin findings. Here, we aimed to report a malignant melanoma case presenting with lumbar vertebra fracture, which is a unique form of presentation.\u0000Case description: A 31-year-old male patient was admitted to the internal medicine outpatient clinic with complaints of low back pain and inability to walk 15 days ago. After the first hour sedimentation value was found to be 101 in the examinations of the patient who came with the complaint of low back pain, he was referred to the hematology department with the preliminary diagnosis of multiple myeloma. Bone marrow aspiration and biopsy was performed. Non-hematopoietic cells were observed in bone marrow aspiration. L2 vertebra fracture was detected in lumbar MRI of the patient with bilateral limitation of movement in the lower extremities. The patient with L2 vertebral fracture was transferred to the neurosurgery service for operation. The patient was diagnosed with malignant melanoma after the frozen biopsy sent after the operation and the previous bone marrow biopsy. \u0000Conclusions: Bone marrow infiltration can be seen in malignant melanoma patients. However, a malignant melanoma patient presented with lombar vertebra fracture has not been reported before in the literature. \u0000","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology &amp; Oncology Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130843227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}